0 false false false false false false false false false false true false false false false false false No description of principal activity 2023-02-01 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 14794830 2023-02-01 2024-01-31 14794830 2024-01-31 14794830 2023-01-31 14794830 core:PlantMachinery 2023-02-01 2024-01-31 14794830 bus:Director1 2023-02-01 2024-01-31 14794830 core:PlantMachinery 2024-01-31 14794830 core:WithinOneYear 2024-01-31 14794830 core:ShareCapital 2024-01-31 14794830 core:RetainedEarningsAccumulatedLosses 2024-01-31 14794830 bus:SmallEntities 2023-02-01 2024-01-31 14794830 bus:AuditExemptWithAccountantsReport 2023-02-01 2024-01-31 14794830 bus:SmallCompaniesRegimeForAccounts 2023-02-01 2024-01-31 14794830 bus:PrivateLimitedCompanyLtd 2023-02-01 2024-01-31 14794830 bus:FullAccounts 2023-02-01 2024-01-31
COMPANY REGISTRATION NUMBER: 14794830
Bio Wear Ltd
Filleted Unaudited Financial Statements
31 January 2024
Bio Wear Ltd
Statement of Financial Position
31 January 2024
2024
Note
£
£
Fixed assets
Tangible assets
4
1,352
Current assets
Cash at bank and in hand
23
Creditors: amounts falling due within one year
5
5,409
-------
Net current liabilities
5,386
-------
Total assets less current liabilities
( 4,034)
-------
Net liabilities
( 4,034)
-------
Bio Wear Ltd
Statement of Financial Position (continued)
31 January 2024
2024
Note
£
£
Capital and reserves
Called up share capital
1
Profit and loss account
( 4,035)
-------
Shareholders deficit
( 4,034)
-------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the year ending 31 January 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 15 October 2024 , and are signed on behalf of the board by:
J A Walton
Director
Company registration number: 14794830
Bio Wear Ltd
Notes to the Financial Statements
Year ended 31 January 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 15 Rudchester Close, Newcastle upon Tyne, NE15 9BW, United Kingdom.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Transition to FRS 102
The entity transitioned from previous UK GAAP to FRS 102 as at 1 February 2022. Details of how FRS 102 has affected the reported financial position and financial performance is given in note 7.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Plant and machinery
-
25% reducing balance
Computer equipment
-
25% reducing balance
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Tangible assets
Plant and machinery
Equipment
Total
£
£
£
Cost
At 1 February 2023
Additions
218
1,446
1,664
----
-------
-------
At 31 January 2024
218
1,446
1,664
----
-------
-------
Depreciation
At 1 February 2023
Charge for the year
41
271
312
----
-------
-------
At 31 January 2024
41
271
312
----
-------
-------
Carrying amount
At 31 January 2024
177
1,175
1,352
----
-------
-------
5. Creditors: amounts falling due within one year
2024
£
Other creditors
5,409
-------
6. Director's advances, credits and guarantees
Included in creditors due within one year is a directors loan account of £5,149.
7. Transition to FRS 102
These are the first financial statements that comply with FRS 102. The company transitioned to FRS 102 on 1 February 2022.
No transitional adjustments were required in equity or profit or loss for the year.